Presentation
Related topics:
Pharmaceutical/Biotech, Europe, Medical Affairs & Stakeholder Engagement
Availability: FREE
- How pharma can utilise digital programmes to support publication strategy.
- Using materials and real world evidence to reach new KOL audiences.
Speaker
Ian Smyth
Director
MEDNET Consult
Presentation
Related topics:
Pharmaceutical/Biotech, Europe, Medical Affairs & Stakeholder Engagement
Availability: FREE
- Compliance and transparency regulations are causing many pharmaceutical companies to re-evaluate how they pay and partner with external experts.
- How do we define a KOL and what are models for effective KOL engagement in the changing environment?
Speaker
Rob Barker
CEO, Succinct Medical Communications, UK
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
- In the context of spending constraints, and aggressive go-tomarket timelines, the generation of compelling real world evidence of the effectiveness, safety and value of a novel therapy or medical device has never been more challenging.
- Peri- and post-approval evidence requirements, which vary markedly across countries, are increasingly demanding both in terms of data needs, and total research and development cost.
- To navigate this reality, a comprehensive evidence development plan that systematically identifies gaps, and organises and prioritises a synergistic program of scientifically robust real world studies in support of market access is of paramount importance.
- An evidence development plan that is based on a thoughtful and stepwise multi-national data and feasibility assessment strategy, will result in the right evidence to support a product’s value proposition while optimising cost savings and timeline efficiencies.
- Data strategy and feasibility assessment case studies alongside a roadmap for cost and timeline savings in the context of technology enabled programs of research will be presented.
Speakers
Krista A. Payne
Vice President, Late Phase Studies, Real World Evidence
Evidera, Canada
Dimitra Lambrelli
Research Evidence, Real World Evidence
Evidera, UK
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
- Why linking medical affairs strategy and capability together is important.
- How to build capabilities in medical affairs functions at different stages of their growth.
- Future challenges in building medical affairs capability.
- Sharing case study examples.
Speaker
Sophie Hall
Head of Capability Building Practice
Pope Woodhead, UK
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
- Assessing the market through a medical affairs lens.
- How market specific characteristics influence medical affairs capabilities.
- How the market dictates medical affairs size and structure.
- How specific roles within medical affairs vary due to market characteristics.
Speaker
Suma Ramadas
Managing Director, Medical Affairs
Campbell Alliance, USA